In the wake of MD Anderson’s costly failure with IBM’s Watson supercomputer, a Watson backlash brewing in biopharma may lead to a moment of reckoning in life sciences.
Quitting Your Job: Dramatic Exit or Inappropriate?
We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It’s not pretty.
Pharma marketers are producing plenty of exceptional creative work in the DTC realm. There are also plenty that prompt quick checks to make sure that one hasn’t inadvertently clicked over to The Onion.